Interestingly, in breast cancer, CEACAM6 status has been shown to be higher in both ER-positive tamoxifen-resistant breast cancer and HER-positive trastuzumab-resistant breast cancer than in treatment-responsive disease [21, 28], suggesting CEACAM6 as a potential target for the subsequent lines of therapy. Here, ESR1 is linked to breast cancer.